EMERYVILLE, Calif., April 13, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, achieved record first-quarter product sales for its Biossance brand, which is delivering high-growth and is expected to drive much better than expected 2017 results for this business line. Biossance Squalane + Peptide Eye Gel is the #1 selling eye product at SEPHORA.com and the brand’s products are garnering top reviews from leading industry publications.
Top recent reviews:
Biossance Squalane + Probiotic Gel Moisturizer cited by W Magazine as #1 of the “The 10 Best New Moisturizers To Try This Spring.” The magazine notes, “This gel based moisturizer is best for someone looking to reduce dryness and redness.”
Biossance noted by Allure as, “The New Natural Skin-Care Line to Hit Sephora Shelves.” Allure states, “Bottom line: Biossance is clean. But what's most interesting about the company is that its entire line is made with squalane, an extremely hydrating ingredient.”
Biossance is growing from less than 2% of Amyris product revenue in 2016 to more than double what was originally planned for 2017. Amyris expects this pace of growth to continue and the company’s personal care business to once again be one of the fastest-growing personal care businesses in the sector. At the same time, the company’s nutrition business is also expanding significantly with better than expected introduction of Farnesene to Vitamin E oil sales in China. The cost advantage and performance of Amyris products is continuing to deliver significant disruption and growth opportunities for Amyris partners.
“We are excited by the growing contribution Biossance is making to our personal care business and the robust growth we are experiencing in our nutrition business,” said John Melo, President & CEO of Amyris. “We are off to a great start for the year driving growth across our business while pursuing strategic opportunities to improve our financial and competitive position as a leading company in our sector.”
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected 2017 results for Amyris’s personal care business line, the anticipated pace of growth of the company’s personal care business and its expected status as one of the fastest-growing personal care businesses in the sector) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on November 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, Biossance and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.